ABSTRACT
Two dangerous obstetric complications, amniotic fluid embolism and preterm prelabor
rupture of membranes (PROM), can be caused by amniotic fluid (AF) constituents. Disseminated
intravascular coagulation (DIC) is related to the former complication, whereas local
thrombin/plasmin-dependent collagenolysis in the decidua and fetal membranes is associated
with the latter. In AF, most proteins of the coagulation and fibrinolysis system,
known as plasma constituents, have been identified based on the activity and/or presence
of antigen. The AF levels of most of these proteins are low (< 2 to 5% of the respective
maternal plasma levels). However, there are some exceptions: tissue factor (TF), urokinase
plasminogen activator (uPA) and its receptor (uPAR), as well as plasminogen activator
inhibitors. The AF level of fetal fibrinogen is trace, which is a particular exception.
The key enzymes of coagulation and fibrinolysis, thrombin and plasmin, are generated
in AF. Thrombin generation is four- to fivefold higher than in maternal plasma as
measured by the concentration of the prothrombin fragments 1 + 2 (F 1 + 2) and thrombin-antithrombin
complexes, whereas plasmin generation is relatively low as measured by the plasmin–α-2-antiplasmin
complexes. Phosphatidylserine, a phospholipid, and thrombin-activatable fibrinolysis
inhibitor (TAFI) are novel components of AF. Phosphatidylserine contributes to DIC
in AF embolism; TAFI is considered a link between coagulation and fibrinolysis. uPA
and uPAR are the factors contributing to PROM via plasmin-dependent proteolysis. Intriguing
is the assumption that TF and its inhibitor can be risk factors for PROM through thrombin-dependent
activation of matrix prometalloproteinases in the decidua and fetal membranes. It
is unknown whether the amniotic pool of hemostatic components is involved in pre-eclampsia
pathogenesis.
KEYWORDS
Amniotic fluid - procoagulants - anticoagulants - fibrinolysis - PROM
REFERENCES
1
Albrechtsen O K, Trolle D.
A fibrinolytic system in human amniotic fluid.
Acta Haematol.
1955;
14
(6)
376-382
2
Uszyński M, Maciejewski K, Uszyński W, Kuczyński J.
Placenta and myometrium—the two main sources of fibrinolytic components during pregnancy.
Gynecol Obstet Invest.
2001;
52
(3)
189-193
3
Lockwood C J, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F.
The role of decidualization in regulating endometrial hemostasis during the menstrual
cycle, gestation, and in pathological states.
Semin Thromb Hemost.
2007;
33
(1)
111-117
4
Watanabe T, Araki M, Mimuro J, Tamada T, Sakata Y.
Fibrinolytic components in fetal membranes and amniotic fluid.
Am J Obstet Gynecol.
1993;
168
(4)
1283-1289
5
Gulbis B, Jauniaux E, Jurkovic D, Thiry P, Campbell S, Ooms H A.
Determination of protein pattern in embryonic cavities of human early pregnancies:
a means to understand materno-embryonic exchanges.
Hum Reprod.
1992;
7
(6)
886-889
6
Michel P E, Crettaz D, Morier P et al.
Proteome analysis of human plasma and amniotic fluid by Off-Gel isoelectric focusing
followed by nano-LC-MS/MS.
Electrophoresis.
2006;
27
(5–6)
1169-1181
7
Mavrou A, Anagnostopoulos A K, Kolialexi A et al.
Proteomic analysis of amniotic fluid in pregnancies with Turner syndrome fetuses.
J Proteome Res.
2008;
7
(5)
1862-1866
8
Tisi D K, Emard J J, Koski K G.
Total protein concentration in human amniotic fluid is negatively associated with
infant birth weight.
J Nutr.
2004;
134
(7)
1754-1758
9
Cade J F, Hirsh J, Martin M.
Placental barrier to coagulation factors: its relevance to the coagulation defect
at birth and to haemorrhage in the newborn.
BMJ.
1969;
2
(5652)
281-283
10 Brace R A. Physiology of amniotic fluid volume regulation. In: Rao K A, Ross M G,
eds. Amniotic Fluid. Bangalore, India: Prism Books; 1999: 110-132
11
Köttgen E, Hell B, Müller C, Tauber R.
Demonstration of glycosylation variants of human fibrinogen, using the new technique
of glycoprotein lectin immunosorbent assay (GLIA).
Biol Chem Hoppe Seyler.
1988;
369
(10)
1157-1166
12
Kimball M E, Milunsky A, Giannusa P, Carvalho A C.
Amniotic fluid fibrinogen degradation products in the prenatal diagnosis of neural
tube defects.
Am J Obstet Gynecol.
1977;
128
(3)
294-299
13
Lockwood C J, Bach R, Guha A, Zhou X D, Miller W A, Nemerson Y.
Amniotic fluid contains tissue factor, a potent initiator of coagulation.
Am J Obstet Gynecol.
1991;
165
(5 Pt 1)
1335-1341
14
Erez O, Gotsch F, Mazaki-Tovi S et al.
Evidence of maternal platelet activation, excessive thrombin generation, and high
amniotic fluid tissue factor immunoreactivity and functional activity in patients
with fetal death.
J Matern Fetal Neonatal Med.
2009;
22
(8)
672-687
15
Uszyński M, Żekanowska E, Uszyński W, Kuczyński J.
Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and
blood plasma: implications for the mechanism of amniotic fluid embolism.
Eur J Obstet Gynecol Reprod Biol.
2001;
95
(2)
163-166
16
González-Quintero V H, Jiménez J J, Jy W et al.
Elevated plasma endothelial microparticles in preeclampsia.
Am J Obstet Gynecol.
2003;
189
(2)
589-593
17
Thompson A R.
Factor IX and prothrombin in amniotic fluid and fetal plasma: constraints on prenatal
diagnosis of hemophilia B and evidence of proteolysis.
Blood.
1984;
64
(4)
867-874
18
Ludwig H, Metzger H.
Das uterine Placentarbett post partum in Rasterelektronenmikroskop, zugleich ein Beitrag
zur Frage der extravasalen Fibrinbildung.
Arch Gynakol.
1971;
210
251-266
19
McVey J H.
Tissue factor pathway.
Baillieres Clin Haematol.
1999;
12
361-372
20
Zhou J, Liu S, Ma M et al.
Procoagulant activity and phosphatidylserine of amniotic fluid cells.
Thromb Haemost.
2009;
101
(5)
845-851
21
Steiner P E, Lushbaugh C C.
Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected
deaths in obstetrics.
JAMA.
1941;
117
1245-1254
22
Uszyński W, Uszyński M, Zekanowska E.
Thrombin markers in pregnant women: measurements of prothrombin fragments F 1 + 2
and thrombin-antithrombin III complexes (TAT) in the cord blood, the mother's blood
and in amniotic fluid.
[in Polish]
Ginekol Pol.
2004;
75
(8)
595-602
23
Uszyński M, Zekanowska E, Kotzbach M, Uszyński W, Kotzbach R.
Protein C, protein S, and thrombomodulin in amniotic fluid. A preliminary study.
J Perinat Med.
2006;
34
(4)
289-292
24
Uszyński W, Zekanowska E, Uszyński M, Rystok D.
Concentration of annezin in gestational tissues: placenta, fetal membranes, myometrium,
and amniotic fluid.
[in Polish]
Gin Pol.
2006;
77
603-610
25
Uszyński M, Kłyszejko A, Zekanowska E.
Plasminogen, α(2)-antiplasmin and complexes of plasmin-α(2)-antiplasmin (PAP) in amniotic
fluid and blood plasma of parturient women.
Eur J Obstet Gynecol Reprod Biol.
2000;
93
(2)
167-171
26
Uszyński M, Perlik M, Uszyński W, Zekanowska E.
Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues;
measurements and clinical implications.
Eur J Obstet Gynecol Reprod Biol.
2004;
114
(1)
54-58
27
Hajjar K A.
Cellular receptors in the regulation of plasmin generation.
Thromb Haemost.
1995;
74
(1)
294-301
28
Uszyński W, Uszyński M, Zekanowska E.
Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary
study.
Thromb Res.
2007;
119
(2)
241-245
29
Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L.
Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
Thromb Haemost.
1997;
78
(1)
386-391
30
Wang W, Boffa M B, Bajzar L, Walker J B, Nesheim M E.
A study of the mechanism of fibrynolysis by activated thrombin-activatable inhibitor.
J Biol Chem.
1998;
273
27176-27181
31
Gris J C, Neveu S, Tailland M L, Courtieu C, Marès P, Schved J F.
Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance
(moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic
capacity.
Thromb Haemost.
1995;
73
(3)
362-367
32
Vassalli J D.
The urokinase receptor.
Fibrinolysis.
1994;
8
172-181
33
Vadillo-Ortega F, Hernandez A, Gonzalez-Avila G, Bermejo L, Iwata K, Strauss III JF.
Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1
levels in amniotic fluids from pregnancies complicated by premature rupture of membranes.
Am J Obstet Gynecol.
1996;
174
(4)
1371-1376
34
Lijnen H R.
Plasmin and matrix metalloproteinases in vascular remodeling.
Thromb Haemost.
2001;
86
(1)
324-333
35
Erez O, Espinoza J, Chaiworapongsa T et al.
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and
tissue factor pathway inhibitor.
J Matern Fetal Neonatal Med.
2008;
21
(10)
732-744
36
Stephenson C D, Lockwood C J, Ma Y, Guller S.
Thrombin-dependent regulation of matrix metalloproteinase (MMP)-9 levels in human
fetal membranes.
J Matern Fetal Neonatal Med.
2005;
18
(1)
17-22
37
Adachi T, Nakabayashi M, Sakwra M, Ando K.
Involvement of fibrinolytic factors in mid trimester amniotic fluid with development
of severe early-onset preeclampsia.
Semin Thromb Hemost.
1999;
25
(5)
447-450
38
Tanjung M, Siddik H Z, Hariman H et al..
Coagulation and fibrinolysis in preeclampsia and neometes.
Clin Appl Thromb/Hemost.
2005;
11
(4)
467-473
39
Hathaway W, Corrigan J.
Report of Scientific and Standardization Subcommitee on Neonatal Hemostasis.
Thromb Haemost.
1991;
65
323-325
Mieczysław UszyńskiM.D.
Professor, Department of Propedeutics of Medicine, Collegium Medicum in Bydgoszcz
Nicolaus Copernicus University in Toruń, Poland
Email: kizproped@amb.bydgoszcz.pl